The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Actavis Inc (NYSE:ACT) and Valeant Pharmaceuticals International Inc (TSX:VRX, NYSE:VRX) announced that the former has reached an agreement with Valeant Pharmaceuticals’ subsidiary, Medicis Pharmaceutical Corporation, to resolve an outstanding litigation related to Actavis’ ANDA for Clindamycin and Tretinoin Gel (generic version of Ziana®) and ANDA for Imiquimod Cream (generic version of Zyclara®).
Actavis Inc (NYSE:ACT) and Valeant Pharmaceuticals International Inc (TSX:VRX, NYSE:VRX) announced that the former has reached an agreement with Valeant Pharmaceuticals’ subsidiary, Medicis Pharmaceutical Corporation, to resolve an outstanding litigation related to Actavis’ ANDA for Clindamycin and Tretinoin Gel (generic version of Ziana®) and ANDA for Imiquimod Cream (generic version of Zyclara®).
As quoted in the press release:
Under the terms of the agreement related to Actavis’ generic version of Ziana®, Actavis may launch its generic product in July 2016, or earlier under certain circumstances.
Under the terms of the agreement related to Actavis’ generic version of Zyclara®, Actavis may launch its generic product on Jan. 1, 2019, or earlier under certain circumstances.
Click here to read the full Actavis Inc (NYSE:ACT) press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.